Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018)

Historic Preferred Stock Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 2 years, with Q2 2018 value amounting to $93.0 million.

  • Crinetics Pharmaceuticals' Preferred Stock Liabilities changed N/A to $93.0 million in Q2 2018 from the same period last year, while for Jun 2018 it was $93.0 million, marking a year-over-year change of. This contributed to the annual value of $29.7 million for FY2017, which is N/A changed from last year.
  • As of Q2 2018, Crinetics Pharmaceuticals' Preferred Stock Liabilities stood at $93.0 million.
  • Over the past 5 years, Crinetics Pharmaceuticals' Preferred Stock Liabilities peaked at $93.0 million during Q2 2018, and registered a low of $29.7 million during Q4 2017.